OBJECTIVE: Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to be used in psoriatic arthritis in daily practice. The aim of the present study was to assess the change values of PsAID-12 in PsA patients continuing or discontinuing anti-TNF treatment. METHODS: We recruited patients from the Hacettepe University biological database (HUR-BIO). Overall, 70 PsA patients had PsAID-12 score before the initiation of the first anti-TNF treatment. Stopping or switching the anti-TNF treatment due to inefficacy was definitely considered a negative response. Changes were evaluated by the comparison with the baseline PsAID-12 score in compliance with the favorable and unfavorable responses to anti-TNF treatments. The standardized response mean (SRM) was used for determining the response. RESULTS: Seventy (78.6% female) patients were analyzed and their mean age was 45.5 years (12.0 years). The mean follow-up duration was 18.3 months (12.6 months). At baseline, the mean PsAID-12 score was 6.6 (1.5). Physicians stopped or switched the treatment in 28 patients (40.0%) due to the inefficacy of anti-TNF treatment. The ΔPsAID-12 score was 0.25 (1.71) in the patients discontinuing anti-TNF treatment and 3.52 (2.31) in the patients continuing their anti-TNF treatment (p < 0.001). The SRM scores higher for PsAID-12, particularly in the well response to anti-TNF treatments. CONCLUSION: A decrease of 3.5 units in PsAID-12 score shows a favorable response to anti-TNF treatment. Changes in PsAID-12 score had well discrimination capacity for anti-TNF treatments.
OBJECTIVE:Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to be used in psoriatic arthritis in daily practice. The aim of the present study was to assess the change values of PsAID-12 in PsA patients continuing or discontinuing anti-TNF treatment. METHODS: We recruited patients from the Hacettepe University biological database (HUR-BIO). Overall, 70 PsA patients had PsAID-12 score before the initiation of the first anti-TNF treatment. Stopping or switching the anti-TNF treatment due to inefficacy was definitely considered a negative response. Changes were evaluated by the comparison with the baseline PsAID-12 score in compliance with the favorable and unfavorable responses to anti-TNF treatments. The standardized response mean (SRM) was used for determining the response. RESULTS: Seventy (78.6% female) patients were analyzed and their mean age was 45.5 years (12.0 years). The mean follow-up duration was 18.3 months (12.6 months). At baseline, the mean PsAID-12 score was 6.6 (1.5). Physicians stopped or switched the treatment in 28 patients (40.0%) due to the inefficacy of anti-TNF treatment. The ΔPsAID-12 score was 0.25 (1.71) in the patients discontinuing anti-TNF treatment and 3.52 (2.31) in the patients continuing their anti-TNF treatment (p < 0.001). The SRM scores higher for PsAID-12, particularly in the well response to anti-TNF treatments. CONCLUSION: A decrease of 3.5 units in PsAID-12 score shows a favorable response to anti-TNF treatment. Changes in PsAID-12 score had well discrimination capacity for anti-TNF treatments.
Authors: Richard Holland; William Tillett; Eleanor Korendowych; Charlotte Cavill; Nicola Waldron; Melanie Brooke; Neil J McHugh Journal: Ann Rheum Dis Date: 2017-11-16 Impact factor: 19.103
Authors: Laure Gossec; Maarten de Wit; Uta Kiltz; Juergen Braun; Umut Kalyoncu; Rossana Scrivo; Mara Maccarone; Laurence Carton; Kati Otsa; Imre Sooäär; Turid Heiberg; Heidi Bertheussen; Juan D Cañete; Anselm Sánchez Lombarte; Andra Balanescu; Alina Dinte; Kurt de Vlam; Josef S Smolen; Tanja Stamm; Dora Niedermayer; Gabor Békés; Douglas Veale; Philip Helliwell; Andrew Parkinson; Thomas Luger; Tore K Kvien Journal: Ann Rheum Dis Date: 2014-06 Impact factor: 19.103
Authors: Laura C Coates; Arthur Kavanaugh; Philip J Mease; Enrique R Soriano; Maria Laura Acosta-Felquer; April W Armstrong; Wilson Bautista-Molano; Wolf-Henning Boehncke; Willemina Campbell; Alberto Cauli; Luis R Espinoza; Oliver FitzGerald; Dafna D Gladman; Alice Gottlieb; Philip S Helliwell; M Elaine Husni; Thorvardur J Love; Ennio Lubrano; Neil McHugh; Peter Nash; Alexis Ogdie; Ana-Maria Orbai; Andrew Parkinson; Denis O'Sullivan; Cheryl F Rosen; Sergio Schwartzman; Evan L Siegel; Sergio Toloza; William Tuong; Christopher T Ritchlin Journal: Arthritis Rheumatol Date: 2016-03-23 Impact factor: 10.995
Authors: Rubén Queiro; Juan D Cañete; Carlos Montilla; Miguel Abad; María Montoro; Susana Gómez; Ana Cábez Journal: Arthritis Res Ther Date: 2017-03-29 Impact factor: 5.156